Skip To Main Content
Theodore H. Welling on Muck Rack

Theodore H. Welling

As seen in: Nature, Frontiers, HemOnc Today, cn1699.com
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile
Back to Theodore H. Welling’s profile

Articles by Theodore H. Welling

Clonal heterogeneity in human pancreatic ductal adenocarcinoma and its impact on tumor progression

|
By Despoina Kalfakakou, Daniel Cameron, Emily A. Kawaler, Motoyuki Tsuda, Lidong Wang, Qi Su, Sungsik Kim, Xiaohong Jing, Cristina H Hajdu, Amanda Ackermann, Matthew Beier, Dacia Dimartino, Shanmugapriya Selvaraj, Cynthia Loomis, Adriana Heguy, Amanda Lund, Hannah Carter, Rosalie C. Sears, Theodore H. Welling, Igor Dolgalev, Aristotelis Tsirigos, Diane Simeone, Elektra Manolakos, Dylan L. Tamayo, Yoona Shim, Daniel Weissinger, Hayley Zimny, Rosmel Hernandez, Peter Meyn, Kalina Rice
| Nature Verified
Abstract Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer characterized by profound desmoplasia and cellular heterogeneity, which cannot be fully resolved using traditional bulk sequencing approaches.
Open in Who Shared Issue with article?

Establishment and validation of a ubiquitination-related gene signature associated with prognosis in pancreatic duct adenocarcinoma

|
By Saleh Alghamdi, Theodore H. Welling, Edmund Sim, Haotian Fu
| Frontiers
Yangyang Guo1,4†, Zhixuan Wu2†, Kenan Cen1†, Yongheng Bai3, Ying Dai1, Yifeng Mai1*, Kai Hong1* and Liangchen Qu4* 1Department of General Surgery, The First Affiliated Hospital of Ningbo University, Ningbo, China 2Key Laboratory of Diagnosis and Treatment of Severe Hepato-Pancreatic Diseases of Zhejiang Province, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China 3National Key Clinical Specialty (General Surgery), The First Affiliated Hospital of Wenzhou Medical...
Open in Who Shared Issue with article?

Adjuvant regimen has ‘potential’ to change practice in high-risk liver cancer

|
By Mark Leiser Verified, Mindy Valcarcel, Pierce K. H. Chow, Theodore H. Welling
| HemOnc Today Verified
Source/Disclosures Source: Chow P, et al. Abstract CT003. Presented at: American Association for Cancer Research Annual Meeting; April 14-19, 2023; Orlando. Disclosures: F. Hoffmann-La Roche Ltd. funded this study. Chow reports research funding from or advisory roles with AstraZeneca, Bayer, Bristol Myers Squibb, Eisai, Genentech, Ipsen, Merck Sharp & Dohme, Roche, Sirtex Medical and other companies. Please see the abstract for all other researchers’ relevant financial disclosures.
Open in Who Shared Issue with article?

Adjuvant regimen has ‘potential’ to change practice in high-risk liver cancer

|
By Theodore H. Welling
| cn1699.com
Source/Disclosures Published by: Source: Chow P, et al. Abstract CT003. Presented at: American Association for Cancer Research Annual Meeting; April 14-19, 2023; Orlando. Disclosures: F. Hoffmann-La Roche Ltd. funded this study. Chow reports research funding from or advisory roles with AstraZeneca, Bayer, Bristol Myers Squibb, Eisai, Genentech, Ipsen, Merck Sharp & Dohme, Roche, Sirtex Medical and other companies. Please see the abstract for all other researchers’ relevant financial disclosures.
Open in Who Shared Issue with article?
Show More